Money, Partners Available Even As Biotech Values, Outlook Decline
This article was originally published in Scrip
Although biotech stock values continue to fall, all is not grim: capital is available for companies that spend time building relationships with investors and partners are willing to work with firms who act fast when big pharma shows interest.
You may also be interested in...
Amgen’s R&D programs are vitally important as sales of multiple blockbusters continue to drop, but one major late-stage asset had disappointing results and another key drug has an aggressive competitor.
The company has assembled small molecule discovery capabilities for the development of targeted cancer drugs that it believes rivals big pharma efforts and will fulfill patients’ unmet needs.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.